a public good project by the
Synthesis
Company
of California

© 2026

Ignace Vergote | doi.page

0 works0 citations0 h-index

Ignace Vergote

Gynecologic Oncology Group(US)European Union(BE)Universitair Ziekenhuis Leuven(BE)The European Academy of Gynaecological Surgery(BE)VIB-KU Leuven Center for Cancer Biology(BE)Catholic University of America(US)Stanford University(US)KU Leuven(BE)

Publications by Year

Research Areas

Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, Intraperitoneal and Appendiceal Malignancies, Uterine Myomas and Treatments

Most-Cited Works

→ Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer(2010)2,486 cited
→ Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer(2016)2,417 cited
→ Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer(2019)2,180 cited
→ Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer(2019)1,962 cited
→ Epithelial ovarian cancer(2019)1,878 cited
→ Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer(2012)1,873 cited
→

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

(2020)

1,861 cited

→ Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited

→ Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial(2014)1,598 cited

→ Endometrial cancer(2005)1,505 cited